Skip to main content
Clinical Trials/NL-OMON45074
NL-OMON45074
Completed
Not Applicable

The effect of correction of metabolic acidosis in chronic kidney disease on intrarenal RAS activity. - BIC study

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
chronic kidney disease
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
48
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- male or female adult (\>18 years)
  • \- chronic kidney disease stage 4, i.e. eGFR (MDRD) 15\-30 ml/min
  • \- plasma bicarbonate concentration of \<24 and \>15 meq/L, the latter because in that case it seems highly recommended to start sodiumbicarbonate suppletion and not to postpone this

Exclusion Criteria

  • \- plasma bicarbonate level \>24 meq/L or \<15 meq/L
  • \- sodiumbicarbonate use in the 6 months preceeding the study
  • \- a kidney transplant in situ
  • \- heart failure
  • \- liver cirrhosis
  • \- blood pressure \> 140/90 mmHg despite the use of 3 different antihypertensives
  • \- a history of inadherence to medication
  • \- use of calcineurin inhibitors (these immunosuppressive drugs are known to induce metabolic acidosis and influence electrolytes and acid\-base balance)

Outcomes

Primary Outcomes

Not specified

Similar Trials